How does your practice measure up? This tool will tell you"The health care field does not show any signs of slowing in pace or growth, and as many people view health care as a service, it is important to strive for an environment that is high in quality, care, support, and acceptance," writes SUNA's Amy Hull, MSN, WHNP-BC.
AUA issues recommendations on surveillance, opioidsContinuing its participation in the Choosing Wisely campaign, the AUA has added five new recommendations about tests and treatments that physicians and patients should question.
[Quiz]: Baby born with atypical genitalia, XY karyotypeA 3-month old baby born with atypical genitalia has an XY karyotype. The baby undergoes diagnostic laparoscopy. The baby is doing clinically well without medication.
Dear USPSTF: Don’t discount value of PSA in men 70+“We strongly believe that PSA-based prostate cancer screening should be made available, especially to men 70 years and older to decrease the morbidity and mortality of prostate cancer,” write Navin Shah, MD, and Vladimir Ioffe, MD.
Is vasectomy always permanent?
Metastatic PCa: Studies point to new standard of care“Abiraterone should change the treatment paradigm for patients with newly diagnosed metastatic prostate cancer and largely displaces chemotherapy from the current paradigm,” said Sumanta Kumar Pal, MD.
Bone supportive therapy increases likelihood of pain palliationAdministering bone supportive therapy within 1 month prior to starting radium Ra 223 dichloride (Xofigo) may increase the likelihood of achieving pain palliation with the radionuclide therapy and reduce the chance of pain flare, according to the findings of a retrospective study.
PDE-5 inhibitors and melanoma: No causal link foundFindings of a meta-analysis show that phosphodiesterase type 5 inhibitor use is associated with a statistically significant increased risk of melanoma, but they do not support a causal relationship.
Physical inactivity raises bladder cancer riskResearchers have observed an association between a lifetime of inactivity and higher risks for bladder and renal cancers.
How do bladder Ca treatments compare in terms of survival?There are no notable differences in overall survival, disease-specific survival, and progression-free survival between radical cystectomy and bladder-preserving combined modality treatment for muscle-invasive bladder cancer, according to a recent meta-analysis.